BioNTech SE: COVID-19 trials

The registry lists 34 COVID-19 studies with BioNTech SE as lead sponsor. 2 are open to participants now and 24 have results posted.

Phase 1 7Phase 2 15Phase 3 19Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of COVID-19 Vaccine(s) in Children and AdultsRecruitingNCT07798648Phase 3
• A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of AgeRecruitingNCT07730450Phase 4
• A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy PeopleCompletedNCT06683352Phase 1/2Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.CompletedNCT06178991Phase 3Results posted
• A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy IndividualsCompletedNCT05997290Phase 2/3Results posted
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and InfluenzaCompletedNCT05596734Phase 2Results posted
• Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy PeopleCompletedNCT05541861Phase 1Results posted
• A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy IndividualsCompletedNCT05472038Phase 2/3Results posted
• Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of AgeCompletedNCT05310084Phase 3Results posted
• Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy ParticipantsCompletedNCT05004181Phase 2Results posted
• To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.CompletedNCT04955626Phase 3Results posted
• A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial SubjectsCompletedNCT04949490Phase 2Results posted
• Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 YearsCompletedNCT04895982Phase 2Results posted
• COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbiditiesTerminatedNCT04860258Phase 3Results posted
• A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy AdultsCompletedNCT04816669Phase 3Results posted
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy ChildrenCompletedNCT04816643Phase 3Results posted
• To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and OlderCompletedNCT04754594Phase 2/3Results posted
• A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy ParticipantsCompletedNCT04713553Phase 3Results posted
• A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19CompletedNCT04674189Phase 3Results posted
• A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and OlderCompletedNCT04652102Phase 2/3Results posted
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese AdultsCompletedNCT04588480Phase 4Results posted
• A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy AdultsCompletedNCT04537949Phase 1/2Results posted
• A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19CompletedNCT04515147Phase 2Results posted
• A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19CompletedNCT04449276Phase 1Results posted
• A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised AdultsCompletedNCT04380701Phase 1/2Results posted
• Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy IndividualsCompletedNCT04368728Phase 2/3Results posted
• A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of AgeCompletedNCT07300839Phase 3
• A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19CompletedNCT07222384Phase 3
• A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 YearsCompletedNCT07069309Phase 3
• A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy PeopleCompletedNCT06821061Phase 1/2
• A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and ChildrenWithdrawnNCT05630352Phase 1
• A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy ChildrenCompletedNCT05543616Phase 3
• A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19WithdrawnNCT04838847Phase 3
• Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy PopulationCompletedNCT04649021Phase 2